Immunotherapy duo tackles rare nerve cancer in early trial
NCT ID NCT04465643
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This early-phase trial tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) before standard surgery, chemotherapy, or radiation is safe and feasible for people with Neurofibromatosis Type 1 who have a rare malignant peripheral nerve sheath tumor. Only 13 participants were enrolled. The main goals were to check for side effects and see if the drugs could be given without delaying standard treatment. The study does not yet prove whether this combination helps shrink tumors or improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab and ipilimumab (immunotherapy drugs)
- What this could lead to
- If this approach proves safe and feasible, it could lead to larger studies testing whether these drugs can shrink tumors before surgery and improve outcomes for people with this rare nerve cancer.
- What could go wrong
- This is a very small, early-phase trial with only 13 participants, so results may not apply to everyone. The drugs can cause serious immune-related side effects, and it is not yet known if they actually help control the tumor long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE MALIGNANT PERIPHERAL NERVE SHEATH TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins Medical Institution
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.